Paul Spearman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Paul Spearman has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Aaron Derdowski
Departments of Pediatrics, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-2581
2 shared publications- Jason Hammonds
Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America
2 shared publications Lingmei Ding
Departments of Pediatrics, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-2581
2 shared publicationsXuemin Chen
Departments of Pediatrics and Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee,1 Division of Vaccine Research, Institute for Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland,2 Department of Surgery, Duke University, Durham, North Carolina3
2 shared publicationsAnthony DeVico
Departments of Pediatrics and Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee,1 Division of Vaccine Research, Institute for Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland,2 Department of Surgery, Duke University, Durham, North Carolina3
1 shared publicationAyumi Shintani
Departments of Pediatrics and Microbiology and Immunology,1 Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee,2 Aventis Pasteur, Toronto, Ontario, Canada,3 U.S. Military HIV Research Program, Rockville, Maryland4
1 shared publication
Latest Publications
- 1 March 2006
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 12 (9) , 1147-1167
Current Progress in the Development of HIV Vaccines
Abstract: The greatest hope for controlling the expanding HIV epidemic is the development of a preventive HIV vaccine. Despite almost twenty years of effort, the search for an effective HIV vaccine continues at the present time. Advances in the understanding of HIV immunopathogenesis, and especially viral immune evasion mechanisms, have provided important insights into HIV vaccine design. HIV vaccine approaches based solely on recombinant monomeric envelope glycoproteins have failed dramatically and have been discarded. Modern vector technologies with the potential for generating protective cellular immune responses against HIV are undergoing intensive evaluation in clinical trials. Adenoviral vector systems appear to be very promising for this purpose, while the ability of poxvirus-based regimens to elicit potent HIVspecific cellular immune responses in humans is less certain. A number of novel live vector-based approaches are in development. This review presents the current state of the HIV vaccine field, with an emphasis on those vaccines that are in clinical trials or in an advanced stage of preclinical testing. The HIV vaccine field is a very active and challenging one that will continue to push forward our understanding of basic immunology and drive the development of new vaccine technologies. New breakthroughs in methods to generate effective neutralizing antibody responses against HIV are urgently needed.
- 1 March 2006
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 12 (9) , 1147-1167
Current Progress in the Development of HIV Vaccines
Abstract: The greatest hope for controlling the expanding HIV epidemic is the development of a preventive HIV vaccine. Despite almost twenty years of effort, the search for an effective HIV vaccine continues at the present time. Advances in the understanding of HIV immunopathogenesis, and especially viral immune evasion mechanisms, have provided important insights into HIV vaccine design. HIV vaccine approaches based solely on recombinant monomeric envelope glycoproteins have failed dramatically and have been discarded. Modern vector technologies with the potential for generating protective cellular immune responses against HIV are undergoing intensive evaluation in clinical trials. Adenoviral vector systems appear to be very promising for this purpose, while the ability of poxvirus-based regimens to elicit potent HIVspecific cellular immune responses in humans is less certain. A number of novel live vector-based approaches are in development. This review presents the current state of the HIV vaccine field, with an emphasis on those vaccines that are in clinical trials or in an advanced stage of preclinical testing. The HIV vaccine field is a very active and challenging one that will continue to push forward our understanding of basic immunology and drive the development of new vaccine technologies. New breakthroughs in methods to generate effective neutralizing antibody responses against HIV are urgently needed.
- Open Access
- 15 December 2005
- Published by American Society for Microbiology in Journal of Virology
- Vol. 79 (23) , 14804-14814
Induction of Neutralizing Antibodies against Human Immunodeficiency Virus Type 1 Primary Isolates by Gag-Env Pseudovirion Immunization
A major challenge for the development of an effective HIV vaccine is to elicit neutralizing antibodies against a broad array of primary isolates. Monomeric gp120-based vaccine approaches have not been successful in inducing this type of response, prompting a number of approaches designed to recreate the native glycoprotein complex that exists on the viral membrane. Gag-Env pseudovirions are noninfectious viruslike particles that recreate the native envelope glycoprotein structure and have the potential to generate neutralizing antibody responses against primary isolates. In this study, an inducible cell line was created in order to generate Gag-Env pseudovirions for examination of neutralizing antibody responses in guinea pigs. Unadjuvanted pseudovirions generated relatively weak anti-gp120 responses, while the use of a block copolymer water-in-oil emulsion or aluminum hydroxide combined with CpG oligodeoxynucleotides resulted in high levels of antibodies that bind to gp120. Sera from immunized animals neutralized a panel of human immunodeficiency virus (HIV) type 1 primary isolate viruses at titers that were significantly higher than that of the corresponding monomeric gp120 protein. Interpretation of these results was complicated by the occurrence of neutralizing antibodies directed against cellular (non-envelope protein) components of the pseudovirion. However, a major component of the pseudovirion-elicited antibody response was directed specifically against the HIV envelope. These results provide support for the role of pseudovirion-based vaccines in generating neutralizing antibodies against primary isolates of HIV and highlight the potential confounding role of antibodies directed at non-envelope cell surface components.
- 15 December 2005
- Published by American Society for Microbiology in Journal of Virology
- Vol. 79 (23) , 14804-14814
Open AccessInduction of Neutralizing Antibodies against Human Immunodeficiency Virus Type 1 Primary Isolates by Gag-Env Pseudovirion Immunization
A major challenge for the development of an effective HIV vaccine is to elicit neutralizing antibodies against a broad array of primary isolates. Monomeric gp120-based vaccine approaches have not been successful in inducing this type of response, prompting a number of approaches designed to recreate the native glycoprotein complex that exists on the viral membrane. Gag-Env pseudovirions are noninfectious viruslike particles that recreate the native envelope glycoprotein structure and have the potential to generate neutralizing antibody responses against primary isolates. In this study, an inducible cell line was created in order to generate Gag-Env pseudovirions for examination of neutralizing antibody responses in guinea pigs. Unadjuvanted pseudovirions generated relatively weak anti-gp120 responses, while the use of a block copolymer water-in-oil emulsion or aluminum hydroxide combined with CpG oligodeoxynucleotides resulted in high levels of antibodies that bind to gp120. Sera from immunized animals neutralized a panel of human immunodeficiency virus (HIV) type 1 primary isolate viruses at titers that were significantly higher than that of the corresponding monomeric gp120 protein. Interpretation of these results was complicated by the occurrence of neutralizing antibodies directed against cellular (non-envelope protein) components of the pseudovirion. However, a major component of the pseudovirion-elicited antibody response was directed specifically against the HIV envelope. These results provide support for the role of pseudovirion-based vaccines in generating neutralizing antibodies against primary isolates of HIV and highlight the potential confounding role of antibodies directed at non-envelope cell surface components.
- Open Access
- 1 May 2005
- Published by American Society for Microbiology in Journal of Virology
- Vol. 79 (9) , 5537-5547
Pseudovirion Particle Production by Live Poxvirus Human Immunodeficiency Virus Vaccine Vector Enhances Humoral and Cellular Immune Responses
Live-vector-based human immunodeficiency virus (HIV) vaccines are an integral part of a number of HIV vaccine regimens currently under evaluation. Live vectors that carry an intactgaggene are capable of eliciting HIV pseudovirion particle formation from infected host cells. The impact of pseudovirion particle formation on the immune response generated by live HIV vaccine vectors has not been established. In this study, a canarypox HIV vaccine candidate vector expressing HIVgagandenvgenes, vCP205, was modified by the introduction of a glycine-to-alanine coding change in the N-terminal myristylation site ofgagto create Myr−vCP205. This substitution effectively eliminated particle formation without altering the level of protein production. vCP205 and Myr−vCP205 were then directly compared for the ability to induce HIV-specific immune responses in mice. The particle-competent vector vCP205 elicited higher levels of CD8+T-cell responses, as indicated by gamma interferon enzyme-linked immunospot (ELISPOT) assay and intracellular cytokine staining. Humoral responses to Gag and Env were also markedly higher from animals immunized with the particle-competent vector. Furthermore, HIV-specific CD4+T-cell responses were greater among animals immunized with the particle-competent vector. Using a human dendritic cell model of antigen presentation in vitro, vCP205 generated greater ELISPOT responses than Myr−vCP205. These results demonstrate that pseudovirion particle production by live-vector HIV vaccines enhances HIV-specific cellular and humoral immune responses.
- 1 May 2005
- Published by American Society for Microbiology in Journal of Virology
- Vol. 79 (9) , 5537-5547
Open AccessPseudovirion Particle Production by Live Poxvirus Human Immunodeficiency Virus Vaccine Vector Enhances Humoral and Cellular Immune Responses
Live-vector-based human immunodeficiency virus (HIV) vaccines are an integral part of a number of HIV vaccine regimens currently under evaluation. Live vectors that carry an intactgaggene are capable of eliciting HIV pseudovirion particle formation from infected host cells. The impact of pseudovirion particle formation on the immune response generated by live HIV vaccine vectors has not been established. In this study, a canarypox HIV vaccine candidate vector expressing HIVgagandenvgenes, vCP205, was modified by the introduction of a glycine-to-alanine coding change in the N-terminal myristylation site ofgagto create Myr−vCP205. This substitution effectively eliminated particle formation without altering the level of protein production. vCP205 and Myr−vCP205 were then directly compared for the ability to induce HIV-specific immune responses in mice. The particle-competent vector vCP205 elicited higher levels of CD8+T-cell responses, as indicated by gamma interferon enzyme-linked immunospot (ELISPOT) assay and intracellular cytokine staining. Humoral responses to Gag and Env were also markedly higher from animals immunized with the particle-competent vector. Furthermore, HIV-specific CD4+T-cell responses were greater among animals immunized with the particle-competent vector. Using a human dendritic cell model of antigen presentation in vitro, vCP205 generated greater ELISPOT responses than Myr−vCP205. These results demonstrate that pseudovirion particle production by live-vector HIV vaccines enhances HIV-specific cellular and humoral immune responses.
- 1 February 2004
- Published by American Society for Microbiology in Journal of Virology
- Vol. 78 (3) , 1230-1242
A Novel Fluorescence Resonance Energy Transfer Assay Demonstrates that the Human Immunodeficiency Virus Type 1 Pr55 Gag I Domain Mediates Gag-Gag Interactions
Human immunodeficiency virus type 1 (HIV-1) assembly takes place at the plasma membrane of cells and is directed by the Pr55 Gag polyprotein (Gag). One of the essential steps in the assembly process is the multimerization of Gag. We have developed a novel fluorescence resonance energy transfer (FRET) assay for the detection of protein-protein interactions between Gag molecules. We demonstrate that Gag multimerization takes place primarily on cellular membranes, with the majority of these interactions occurring on the plasma membrane. However, distinct sites of Gag-Gag interaction are also present at punctate intracellular locations. The I domain is a functional assembly domain within the nucleocapsid region of Gag that affects particle density, the subcellular localization of Gag, and the formation of detergent-resistant Gag protein complexes. Results from this study provide evidence that the I domain mediates Gag-Gag interactions. Using Gag-fluorescent protein fusion constructs that were previously shown to define the minimal I domain within HIV-1 Pr55 Gag , we show by FRET techniques that protein-protein interactions are greatly diminished when Gag proteins lacking the I domain are expressed. Gag-Tsg101 interactions are also seen in living cells and result in a shift of Tsg101 to the plasma membrane. The results within this study provide direct evidence that the I domain mediates protein-protein interactions between Gag molecules. Furthermore, this study establishes FRET as a powerful tool for the detection of protein-protein interactions involved in retrovirus assembly.
- 1 February 2004
- Published by American Society for Microbiology in Journal of Virology
- Vol. 78 (3) , 1230-1242
A Novel Fluorescence Resonance Energy Transfer Assay Demonstrates that the Human Immunodeficiency Virus Type 1 Pr55 Gag I Domain Mediates Gag-Gag Interactions
Human immunodeficiency virus type 1 (HIV-1) assembly takes place at the plasma membrane of cells and is directed by the Pr55 Gag polyprotein (Gag). One of the essential steps in the assembly process is the multimerization of Gag. We have developed a novel fluorescence resonance energy transfer (FRET) assay for the detection of protein-protein interactions between Gag molecules. We demonstrate that Gag multimerization takes place primarily on cellular membranes, with the majority of these interactions occurring on the plasma membrane. However, distinct sites of Gag-Gag interaction are also present at punctate intracellular locations. The I domain is a functional assembly domain within the nucleocapsid region of Gag that affects particle density, the subcellular localization of Gag, and the formation of detergent-resistant Gag protein complexes. Results from this study provide evidence that the I domain mediates Gag-Gag interactions. Using Gag-fluorescent protein fusion constructs that were previously shown to define the minimal I domain within HIV-1 Pr55 Gag , we show by FRET techniques that protein-protein interactions are greatly diminished when Gag proteins lacking the I domain are expressed. Gag-Tsg101 interactions are also seen in living cells and result in a shift of Tsg101 to the plasma membrane. The results within this study provide direct evidence that the I domain mediates protein-protein interactions between Gag molecules. Furthermore, this study establishes FRET as a powerful tool for the detection of protein-protein interactions involved in retrovirus assembly.
- 9 December 2003
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 100 (25) , 15154-15159
Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production
Human cells resist viral infections by a variety of mechanisms. Viruses must overcome host cell restrictions to successfully reproduce their genetic material. Here, we identify a host restriction to viral replication that acts at the stage of particle assembly. Viral protein U (Vpu) is an HIV-1 accessory protein that enhances particle assembly and release in most human cells, but not in simian cells. By using human-simian cell heterokaryons, we show that the inhibition of assembly in human cells is dominant. Vpu overcomes the block to assembly in human cells and in human-simian heterokaryons. The HIV-1 vpu gene may have evolved to counteract an assembly restriction that is present in human cells.
- 9 December 2003
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 100 (25) , 15154-15159
Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production
Human cells resist viral infections by a variety of mechanisms. Viruses must overcome host cell restrictions to successfully reproduce their genetic material. Here, we identify a host restriction to viral replication that acts at the stage of particle assembly. Viral protein U (Vpu) is an HIV-1 accessory protein that enhances particle assembly and release in most human cells, but not in simian cells. By using human-simian cell heterokaryons, we show that the inhibition of assembly in human cells is dominant. Vpu overcomes the block to assembly in human cells and in human-simian heterokaryons. The HIV-1 vpu gene may have evolved to counteract an assembly restriction that is present in human cells.
- Open Access
- 1 February 2003
- Published by American Society for Microbiology in Journal of Virology
- Vol. 77 (3) , 1916-1926
Independent Segregation of Human Immunodeficiency Virus Type 1 Gag Protein Complexes and Lipid Rafts
Formation of human immunodeficiency virus type 1 (HIV-1) particles takes place at the plasma membrane of cells and is directed by the Pr55Gag polyprotein. A functional assembly domain (the M domain) within the N-terminal portion of Pr55Gag mediates the interaction of Gag with cellular membranes. However, the determinants that provide specificity for assembly on the plasma membrane, as opposed to intracellular membranes, have not been identified. Recently, it was reported that Pr55Gag interacts with lipid raft microdomains of the plasma membrane. We sought to identify the domains within Pr55Gag that contribute to lipid raft association of Gag. Here we demonstrate that the I domain is required for interaction with detergent-resistant membrane fractions (DRMs). Mutation of key I-domain residues or loss of myristylation abrogated the association of Gag with DRMs. Thus, the I domain and the M domain combine to mediate Gag-lipid raft interactions as defined by these biochemical criteria. However, Gag protein complexes defined by flotation studies were much denser than classical lipid rafts, failed to incorporate classical lipid raft marker proteins, and were not disrupted by cholesterol extraction. Large sheets of Gag protein were identified in DRM fractions upon examination by electron microscopy. These results indicate that HIV-1 Pr55Gag forms detergent-resistant complexes at the cellular periphery that are distinct from lipid raft microdomains.
- 1 February 2003
- Published by American Society for Microbiology in Journal of Virology
- Vol. 77 (3) , 1916-1926
Open AccessIndependent Segregation of Human Immunodeficiency Virus Type 1 Gag Protein Complexes and Lipid Rafts
Formation of human immunodeficiency virus type 1 (HIV-1) particles takes place at the plasma membrane of cells and is directed by the Pr55Gag polyprotein. A functional assembly domain (the M domain) within the N-terminal portion of Pr55Gag mediates the interaction of Gag with cellular membranes. However, the determinants that provide specificity for assembly on the plasma membrane, as opposed to intracellular membranes, have not been identified. Recently, it was reported that Pr55Gag interacts with lipid raft microdomains of the plasma membrane. We sought to identify the domains within Pr55Gag that contribute to lipid raft association of Gag. Here we demonstrate that the I domain is required for interaction with detergent-resistant membrane fractions (DRMs). Mutation of key I-domain residues or loss of myristylation abrogated the association of Gag with DRMs. Thus, the I domain and the M domain combine to mediate Gag-lipid raft interactions as defined by these biochemical criteria. However, Gag protein complexes defined by flotation studies were much denser than classical lipid rafts, failed to incorporate classical lipid raft marker proteins, and were not disrupted by cholesterol extraction. Large sheets of Gag protein were identified in DRM fractions upon examination by electron microscopy. These results indicate that HIV-1 Pr55Gag forms detergent-resistant complexes at the cellular periphery that are distinct from lipid raft microdomains.
- 1 January 2003
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 1 (1) , 101-120
HIV Vaccine Development: Lessons from the Past and Promise for the Future
The global HIV epidemic continues to expand, exceeding previous predictions and causing tremendous suffering. An effective vaccine represents the best hope to curtail the HIV epidemic. The past fifteen years of HIV vaccine clinical trials have not identified an ideal HIV vaccine, but have provided many valuable lessons that contribute to the current generation of promising HIV vaccine regimens. An enhanced understanding of HIV and SIV immunopathogenesis has facilitated the design of vaccination regimens that elicit specific immune responses and effector mechanisms. Intensive investigation of recombinant gp120 subunit vaccines has revealed a previously unexpected complexity in eliciting neutralizing antibodies that are active against primary isolate viruses. The importance of CD8+ CTL responses in controlling HIV and SIV viremia has led to a series of vaccine candidates that effectively induce these responses. Proof that vaccination can prevent SIV / HIV disease has now been obtained in simian models of AIDS. A number of promising HIV vaccine regimens are currently being evaluated in human trials, and the pipeline of new vaccine vectors and combination regimens appears robust. Although challenges to the development of a safe and effective global HIV vaccine remain, the outlook for HIV vaccines in the future is bright.
- 1 January 2003
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 1 (1) , 101-120
HIV Vaccine Development: Lessons from the Past and Promise for the Future
The global HIV epidemic continues to expand, exceeding previous predictions and causing tremendous suffering. An effective vaccine represents the best hope to curtail the HIV epidemic. The past fifteen years of HIV vaccine clinical trials have not identified an ideal HIV vaccine, but have provided many valuable lessons that contribute to the current generation of promising HIV vaccine regimens. An enhanced understanding of HIV and SIV immunopathogenesis has facilitated the design of vaccination regimens that elicit specific immune responses and effector mechanisms. Intensive investigation of recombinant gp120 subunit vaccines has revealed a previously unexpected complexity in eliciting neutralizing antibodies that are active against primary isolate viruses. The importance of CD8+ CTL responses in controlling HIV and SIV viremia has led to a series of vaccine candidates that effectively induce these responses. Proof that vaccination can prevent SIV / HIV disease has now been obtained in simian models of AIDS. A number of promising HIV vaccine regimens are currently being evaluated in human trials, and the pipeline of new vaccine vectors and combination regimens appears robust. Although challenges to the development of a safe and effective global HIV vaccine remain, the outlook for HIV vaccines in the future is bright.